Treatment of bacillary dysentery in Vietnamese children: two doses of ofloxacin versus 5-days nalidixic acid

Trans R Soc Trop Med Hyg. 2000 May-Jun;94(3):323-6. doi: 10.1016/s0035-9203(00)90343-2.

Abstract

Nalidixic acid (NA: 55 mg/kg daily for 5 days) is the recommended treatment for uncomplicated bacillary dysentery in areas where multidrug-resistant Shigella are prevalent. An open randomized comparison of this NA regimen with 2 doses of ofloxacin (total 15 mg/kg) was conducted in 1995/96 in 135 Vietnamese children with fever and bloody diarrhoea. Sixty-six children with a bacterial pathogen isolated were eligible for analysis. Of the 63 Shigella isolates, 39 (62%) were resistant to multiple antibiotics. Resolution times for fever and diarrhoea were similar in the 2 groups, but excretion time of stool pathogen was significantly longer in the NA recipients [median (range) days 1 (1-9) vs 1 (1-2), P = 0.001]. There were 9 (25%) treatment failures in the NA regimen and 3 (10%) in the ofloxacin group; P = 0.1. Two patients had NA-resistant Shigella flexneri. One of these isolates was selected during NA treatment. From a clinical and public health standpoint a 2-dose regimen of ofloxacin is preferable to nalidixic acid in the treatment of bacillary dysentery.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Anti-Infective Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Dysentery, Bacillary / drug therapy*
  • Dysentery, Bacillary / microbiology
  • Humans
  • Infant
  • Nalidixic Acid / therapeutic use*
  • Ofloxacin / therapeutic use*
  • Shigella flexneri / isolation & purification*
  • Shigella sonnei / isolation & purification*
  • Survival Analysis
  • Treatment Outcome

Substances

  • Anti-Infective Agents
  • Nalidixic Acid
  • Ofloxacin